Advanced stage mucinous epithelial ovarian cancer: The Hellenic Cooperative Oncology Group experience

Pectasides, Dimitrios; Fountzilas, George; Aravantinos, G.; Kalofonos, Haralabos P.; Efstathiou, Eleni; Salamalekis, E.; Farmakis, Dimitrios; Skarlos, Dimosthenis; Briasoulis, Evangelos; Economopoulos, Theofanis; Dimopoulos, Meletios Α.

doi:10.1016/j.ygyno.2004.12.056

Cited by 154 publications

(129 citation statements)

References 19 publications

Supporting

Mentioning

114

Contrasting

Unclassified

Order By: Relevance

“…41) Brain metastases from gynecological cancers are usually found in association with widely disseminated disease. 1,19,29,31) Our study found that 14 of 18 patients had active extracranial diseases at diagnosis of brain metastases. These results indicate that patients with brain metastases usually have disseminated systemic diseases at the time of clinical appearance of brain metastases.…”

Section: Discussionmentioning

confidence: 58%

Treatment and Prognosis of Brain Metastases From Gynecological Cancers

Ogawa

Yoshii

Aoki

et al. 2008

Neurol. Med. Chir.(Tokyo)

View full text Add to dashboard Cite

Brain metastases from gynecological cancers were retrospectively investigated in 18 patients who were treated between 1985 and 2006. Six patients received surgical resection followed by radiotherapy, and 12 patients received only radiotherapy. The median survival for all patients was 4.1 months (range 0.7-48.2 months), and the actuarial survival rates were 11% at both 12 months and 24 months. Univariate analysis showed that treatment modality, extracranial disease status, total radiation dose, number of brain metastases, and Karnofsky performance status (KPS) all had statistically significant impacts on survival. Two patients survived for more than 2 years, and both had single brain metastasis, inactive extracranial disease, 90-100% KPS, and were treated with surgical resection followed by radiotherapy. Improvements in neurological symptoms were observed in 10 of the 12 patients treated with palliative radiotherapy, with median duration of 3.1 months (range 1.5-4.5 months). The prognoses for patients with brain metastases from gynecological cancers were generally poor, although selected patients may survive longer with intensive brain tumor treatment. Palliative radiotherapy was effective in improving the quality of the remaining life for patients with unfavorable prognoses.

show abstract

Section: Discussionmentioning

confidence: 58%

Treatment and Prognosis of Brain Metastases From Gynecological Cancers

Ogawa

Yoshii

Aoki

et al. 2008

Neurol. Med. Chir.(Tokyo)

View full text Add to dashboard Cite

show abstract

“…Additionally, CCC of the ovary was implied to show resistance to conventional platinum-based chemotherapy (5,6). Recent studies confirmed the evidence in the analysis of measurable CCC patients: response was observed in 11-45% with conventional platinum-based regimen, whereas patients with serous subtype showed a significantly higher response rate of 73-81% (7,8).…”

Section: Introductionmentioning

confidence: 84%

Adjuvant chemotherapy with irinotecan hydrochloride and cisplatin for clear cell carcinoma of the ovary

Takano

Kikuchi²,

Yaegashi³

et al. 2006

Oncol Rep

View full text Add to dashboard Cite

Abstract. Clear cell carcinoma (CCC) of the ovary has distinct characteristics showing resistance to conventional platinum-based regimen. Our aim was to evaluate the effects of combination therapy with irinotecan hydrochloride and cisplatin (CPT-P), comparing to regimen with paclitaxel and platinum (TP). We retrospective reviewed 172 patients with complete surgical staging procedures including lymphadenenctomy. Forty-six patients received CPT-P and 126 patients were treated with TP. Survival of the two groups was compared. Between CPT-P group and TP group, there was no significant difference in median age, performance status, FIGO stage, rate of optimal cytoreduction, and follow-up period. There was no significant difference in progressionfree survival of patients with stage I tumors (p=0.95) and suboptimally debulked stage II-IV tumors (p=0.92). Although there was no significant difference of overall survival, progression-free survival of CPT-P group was significantly better than that of TP group in optimally debulked stage II-IV (p=0.03). Multiple regression survival analysis revealed CPT-P regimen (p=0.02) and residual tumor diameter (p<0.01) were both independent prognostic factors in stage II-IV tumors. The combination of CPT-P was shown to have a potential therapeutic benefit for advanced CCC of the ovary, especially for cases with optimal debulking surgery. However, this is a limited retrospective study, therefore we recommend that the CPT-P regimen be evaluated in a larger prospective study.

show abstract

“…However, advanced MAC has a poorer prognosis than other histopathologic subgroups (6). MAC's low response (26-42%) to conventional platinum-based chemotherapy is associated with a poor prognosis because chemosensitivity is one of the main prognostic factors for patients with advanced EOC (7)(8)(9)(10). Although MAC is known to be resistant to platinum/taxane combination chemotherapy (10), patients with MAC are usually treated with this first-line chemotherapy regimen.…”

Section: Discussionmentioning

confidence: 99%

“…Compared to serous adenocarcinoma (SAC), which is the most common histopathologic subgroup of EOC, MAC is relatively resistant to the conventional platinum or taxane-based chemotherapy, thereby leading to a poor prognosis (7)(8)(9)(10). It has been reported that MAC differs from SAC pathologically and cytogenetically, and more closely resembles colorectal cancer (11).…”

Section: Introductionmentioning

confidence: 99%

Cetuximab inhibits the growth of mucinous ovarian carcinoma tumor cells lacking KRAS gene mutations

Sato

Saga

Mizukami³

et al. 2012

Oncol Rep

View full text Add to dashboard Cite

Abstract. The purpose of this study was to explore the possibility of targeted molecular therapy with anti-epidermal growth factor receptor (anti-EGFR) antibody (cetuximab) for the treatment of mucinous ovarian carcinoma. We analyzed EGFR protein expression and KRAS gene mutations in 5 mucinous ovarian carcinoma cell lines RMUG-L, RMUG-S, MN-1, OMC-1 and MCAS and evaluated the in vitro and in vivo effects of cetuximab on each. EGFR expression was observed in all cell lines except for MN-1 cells, and a KRAS gene mutation at codon 12 was detected only in the MCAS cell line. Cetuximab inhibited RMUG-L and OMC-1 cell growth in vitro and completely blocked RMUG-L tumor growth in vivo. On the other hand, cetuximab did not affect MCAS cell growth in vitro and only partially reduced the MCAS tumor growth in vivo. These results suggest the possibility of targeted molecular therapy with cetuximab for mucinous ovarian carcinoma cells lacking a KRAS gene mutation. IntroductionOvarian cancer is the fifth leading cause of cancer-relateddeath in the United States. Ovarian cancer was reported in ~22,000 women in 2010, ~14,000 of whom ultimately died of this disease (1). Since most patients with early-stage ovarian cancer seldom have symptoms, by the time they are diagnosed, >75% are already in the advanced stage (2). The standard treatment for ovarian cancer is cytoreductive surgery with platinum/taxane combination chemotherapy. Although ovarian cancer is generally sensitive to chemotherapy (3,4), there are cases that exhibit both natively drug-resistant tumors as well as tumors that eventually acquire drug tolerance. The 5-year survival rate is only 40% and has not improved in the last decade (1). Therefore, new strategies, especially targeted molecular therapy, require more attention in order to improve the prognosis of ovarian cancer.Mucinous ovarian adenocarcinoma (MAC) accounts for 10-14% of all types of epithelial ovarian cancers (EOC) (5,6). Compared to serous adenocarcinoma (SAC), which is the most common histopathologic subgroup of EOC, MAC is relatively resistant to the conventional platinum or taxane-based chemotherapy, thereby leading to a poor prognosis (7-10). It has been reported that MAC differs from SAC pathologically and cytogenetically, and more closely resembles colorectal cancer (11). These results suggest that therapeutic agents that are effective in treating colorectal cancer may also be effective for treating MAC.Epidermal growth factor (EGF) and its receptor (EGFR) are reportedly involved in the growth and extension of malignant tumors (12). In particular, EGFR overexpression has been observed in various malignant tumors (13). Further, EGFR overexpression has been reported to be a poor prognostic factor for various malignant tumors (14,15). It has been reported that EGFR is expressed in 48% of MAC tumors, and its expression is correlated with the histologic grade, stage and death rate (16).Cetuximab, an anti-EGFR monoclonal antibody, is a molecular-targeted therapeutic agent that was produced as a human...

show abstract

Advanced stage mucinous epithelial ovarian cancer: The Hellenic Cooperative Oncology Group experience

Cited by 154 publications

References 19 publications

Treatment and Prognosis of Brain Metastases From Gynecological Cancers

Treatment and Prognosis of Brain Metastases From Gynecological Cancers

Adjuvant chemotherapy with irinotecan hydrochloride and cisplatin for clear cell carcinoma of the ovary

Cetuximab inhibits the growth of mucinous ovarian carcinoma tumor cells lacking KRAS gene mutations

Contact Info

Product

Resources

About